- 1. What is SARS-CoV-2? What is COVID-19?
- 2. Where do coronaviruses come from?
- 3. Is this virus comparable to SARS or to the seasonal flu?
- 4. What is the mode of transmission? How (easily) does it spread?
- 5. When is a person infectious?
- 6. How severe is COVID-19 infection?
- 7. Are some people more at risk than others?
- 8. Are children also at risk of infection and what is their potential role in transmission?
- 9. Is there a treatment for the COVID-19 disease?
- 10. When should I be tested for COVID-19?
- JOIN NB ON SOCIAL MEDIA
It has become an issue of a total world pandemic concerning the Covid-19 virus that struck the planet earth. permit me to say, this is the only disaster that has struck the earth and has taken away one of the most adored thing in the whole wide world (Religion and Commerce).
Who will believe that a day will come when every one (especially Nigerians) will close down worship centers. it is in the vein that Naijabiography Team had to put up some vital and key thing you should know about the virus.
below are 10 Facts Nobody will tell you about CoronaVirus even though you need to know.
1. What is SARS-CoV-2? What is COVID-19?
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the name given to the 2019 novel coronavirus. COVID-19 is the name given to the disease associated with the virus. SARS-CoV-2 is a new strain of coronavirus that has not been previously identified in humans.
2. Where do coronaviruses come from?
Coronaviruses are viruses that circulate among animals with some of them also known to infect humans.
Bats are considered natural hosts of these viruses yet several other species of animals are also known to act as sources. For instance, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is transmitted to humans from camels, and Severe Acute Respiratory Syndrome Coronavirus-1 (SARS-CoV-1) is transmitted to humans from civet cats. More information on coronaviruses can be found in the ECDC factsheet.
3. Is this virus comparable to SARS or to the seasonal flu?
The novel coronavirus detected in China in 2019 is closely related genetically to the SARS-CoV-1 virus. SARS emerged at the end of 2002 in China, and it caused more than 8 000 cases in 33 countries over a period of eight months. Around one in ten of the people who developed SARS died.
As of 30 March 2020, the COVID-19 outbreak had caused over 700 000 cases worldwide since the first case was reported in China in January 2020. Of these, more than 30 000 are known to have died.
While the viruses that cause both COVID-19 and seasonal influenza are transmitted from person-to-person and may cause similar symptoms, the two viruses are very different and do not behave in the same way.
ECDC estimates that between 15 000 and 75 000 people die prematurely due to causes associated with seasonal influenza infection each year in the EU, the UK, Norway, Iceland and Liechtenstein. This is approximately 1 in every 1 000 people who are infected. Despite the relatively low mortality rate for seasonal influenza, many people die from the disease due to the large number of people who contract it each year. The concern about COVID-19 is that, unlike influenza, there is no vaccine and no specific treatment for the disease. It also appears to be more transmissible than seasonal influenza. As it is a new virus, nobody has prior immunity, which means that the entire human population is potentially susceptible to SARS-CoV-2 infection.
4. What is the mode of transmission? How (easily) does it spread?
While animals are believed to be the original source, the virus spread is now from person to person (human-to-human transmission). There is not enough epidemiological information at this time to determine how easily this virus spreads between people, but it is currently estimated that, on average, one infected person will infect between two and three other people.
The virus seems to be transmitted mainly via small respiratory droplets through sneezing, coughing, or when people interact with each other for some time in close proximity (usually less than one metre). These droplets can then be inhaled, or they can land on surfaces that others may come into contact with, who can then get infected when they touch their nose, mouth or eyes. The virus can survive on different surfaces from several hours (copper, cardboard) up to a few days (plastic and stainless steel). However, the amount of viable virus declines over time and may not always be present in sufficient numbers to cause infection.
The incubation period for COVID-19 (i.e. the time between exposure to the virus and onset of symptoms) is currently estimated to bet between one and 14 days.
We know that the virus can be transmitted when people who are infected show symptoms such as coughing. There is also some evidence suggesting that transmission can occur from a person that is infected even two days before showing symptoms; however, uncertainties remain about the effect of transmission by non-symptomatic persons.
5. When is a person infectious?
The infectious period may begin one to two days before symptoms appear, but people are likely most infectious during the symptomatic period, even if symptoms are mild and very non-specific. The infectious period is now estimated to last for 7-12 days in moderate cases and up to two weeks on average in severe cases.
6. How severe is COVID-19 infection?
Preliminary data from the EU/EEA (from the countries with available data) show that around 20-30% of diagnosed COVID-19 cases are hospitalised and 4% have severe illness. Hospitalisation rates are higher for those aged 60 years and above, and for those with other underlying health conditions
7. Are some people more at risk than others?
Elderly people above 70 years of age and those with underlying health conditions (e.g. hypertension, diabetes, cardiovascular disease, chronic respiratory disease and cancer) are considered to be more at risk of developing severe symptoms. Men in these groups also appear to be at a slightly higher risk than females.
8. Are children also at risk of infection and what is their potential role in transmission?
Children make up a very small proportion of reported COVID-19 cases, with about 1% of all cases reported being under 10 years, and 4% aged 10-19 years. Children appear as likely to be infected as adults, but they have a much lower risk than adults of developing symptoms or severe disease. There is still some uncertainty about the extent to which asymptomatic or mildly symptomatic children transmit disease.
9. Is there a treatment for the COVID-19 disease?
There is no specific treatment or vaccine for this disease.
Healthcare providers are mostly using a symptomatic approach, meaning they treat the symptoms rather than target the virus, and provide supportive care (e.g. oxygen therapy, fluid management) for infected persons, which can be highly effective.
In severe and critically ill patients, a number of drugs are being tried to target the virus, but the use of these need to be more carefully assessed in randomised controlled trials. Several clinical trials are ongoing to assess their effectiveness but results are not yet available.
As this is a new virus, no vaccine is currently available. Although work on a vaccine has already started by several research groups and pharmaceutical companies worldwide, it may be months to more than a year before a vaccine has been tested and is ready for use in humans.
10. When should I be tested for COVID-19?
Current advice for testing depends on the stage of the outbreak in the country or area where you live. Testing approaches will be adapted to the situation at national and local level. National authorities may decide to test only subgroups of suspected cases based on the national capacity to test, the availability of necessary equipment for testing, the level of community transmission of COVID-19, or other criteria.
As a resource conscious approach, ECDC has suggested that national authorities may consider prioritising testing in the following groups:
- hospitalised patients with severe respiratory infections;
- symptomatic healthcare staff including those with mild symptoms;
- cases with acute respiratory infections in hospital or long-term care facilities;
- patients with acute respiratory infections or influenza-like illness in certain outpatient clinics or hospitals;
- elderly people with underlying chronic medical conditions such as lung disease, cancer, heart failure, cerebrovascular disease, renal disease, liver disease, diabetes, and immunocompromising conditions.